Patent · US Active

Imidazo[4,5-C]quinolines as DNA-PK inhibitors

US9598408B2 · kind B2 · utility

5Cited by

7References

3Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Thomas Fuchss · Bensheim, DE
Werner Mederski · Zwingenberg, DE
Frank Zenke · Darmstadt, DE

Key dates

Filing date	Apr 1, 2015
Grant date	Mar 21, 2017
Priority date	—
Expiry date	Apr 3, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y207/11001
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compounds of the formulae (I) and (II) in which R1, R2, R3, R4, R5, R8, X and m have the meaning indicated in the claims, and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.